| Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions V Krishnan, MH Han, DL Graham, O Berton, W Renthal, SJ Russo, ... Cell 131 (2), 391-404, 2007 | 2431 | 2007 |
| Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress O Berton, CA McClung, RJ DiLeone, V Krishnan, W Renthal, SJ Russo, ... Science 311 (5762), 864-868, 2006 | 2389 | 2006 |
| Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse DL Graham, S Edwards, RK Bachtell, RJ DiLeone, M Rios, DW Self Nature neuroscience 10 (8), 1029-1037, 2007 | 476 | 2007 |
| Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS T Miller, M Cudkowicz, PJ Shaw, PM Andersen, N Atassi, RC Bucelli, ... New England Journal of Medicine 383 (2), 109-119, 2020 | 432 | 2020 |
| CREB regulation of nucleus accumbens excitability mediates social isolation–induced behavioral deficits DL Wallace, MH Han, DL Graham, TA Green, V Vialou, SD Iniguez, ... Nature neuroscience 12 (2), 200-209, 2009 | 361 | 2009 |
| Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS TM Miller, ME Cudkowicz, A Genge, PJ Shaw, G Sobue, RC Bucelli, ... New England Journal of Medicine 387 (12), 1099-1110, 2022 | 283 | 2022 |
| Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study EH Thijssen, R La Joie, A Strom, C Fonseca, L Iaccarino, A Wolf, S Spina, ... The Lancet Neurology 20 (9), 739-752, 2021 | 249 | 2021 |
| Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models A McCampbell, T Cole, AJ Wegener, GS Tomassy, A Setnicka, BJ Farley, ... The Journal of clinical investigation 128 (8), 3558-3567, 2018 | 220 | 2018 |
| The influence of ΔFosB in the nucleus accumbens on natural reward-related behavior DL Wallace, V Vialou, L Rios, TL Carle-Florence, S Chakravarty, A Kumar, ... Journal of Neuroscience 28 (41), 10272-10277, 2008 | 219 | 2008 |
| Regulation of anxiety and initiation of sexual behavior by CREB in the nucleus accumbens M Barrot, DL Wallace, CA Bolaños, DL Graham, LI Perrotti, RL Neve, ... Proceedings of the National Academy of Sciences 102 (23), 8357-8362, 2005 | 189 | 2005 |
| Environmental enrichment produces a behavioral phenotype mediated by low cyclic adenosine monophosphate response element binding (CREB) activity in the nucleus accumbens TA Green, IN Alibhai, CN Roybal, CA Winstanley, DEH Theobald, ... Biological psychiatry 67 (1), 28-35, 2010 | 182 | 2010 |
| Trial of cinpanemab in early Parkinson’s disease AE Lang, AD Siderowf, EA Macklin, W Poewe, DJ Brooks, HH Fernandez, ... New England Journal of Medicine 387 (5), 408-420, 2022 | 156 | 2022 |
| Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 M Brys, L Fanning, S Hung, A Ellenbogen, N Penner, M Yang, M Welch, ... Movement Disorders 34 (8), 1154-1163, 2019 | 154 | 2019 |
| Tropomyosin-related kinase B in the mesolimbic dopamine system: region-specific effects on cocaine reward DL Graham, V Krishnan, EB Larson, A Graham, S Edwards, RK Bachtell, ... Biological psychiatry 65 (8), 696-701, 2009 | 135 | 2009 |
| Overexpression of CREB in the nucleus accumbens shell increases cocaine reinforcement in self-administering rats EB Larson, DL Graham, RR Arzaga, N Buzin, J Webb, TA Green, CE Bass, ... Journal of Neuroscience 31 (45), 16447-16457, 2011 | 132 | 2011 |
| Validation of serum neurofilament light chain as a biomarker of Parkinson's disease progression B Mollenhauer, M Dakna, N Kruse, D Galasko, T Foroud, H Zetterberg, ... Movement Disorders 35 (11), 1999-2008, 2020 | 124 | 2020 |
| Progranulin is a chemoattractant for microglia and stimulates their endocytic activity F Pickford, J Marcus, LM Camargo, Q Xiao, D Graham, JR Mo, ... The American journal of pathology 178 (1), 284-295, 2011 | 124 | 2011 |
| Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial AL Boxer, I Qureshi, M Ahlijanian, M Grundman, LI Golbe, I Litvan, ... The Lancet Neurology 18 (6), 549-558, 2019 | 122 | 2019 |
| Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy DL Graham, AJ Gray, JA Joyce, D Yu, J O'Moore, GA Carlson, ... Neuropharmacology 79, 307-313, 2014 | 122 | 2014 |
| Striatal regulation of ΔFosB, FosB, and cFos during cocaine self‐administration and withdrawal EB Larson, F Akkentli, S Edwards, DL Graham, DL Simmons, IN Alibhai, ... Journal of neurochemistry 115 (1), 112-122, 2010 | 96 | 2010 |
